Announced completion of enrollment for 124 patients. After up to a 3-year observation period, primary endpoints will be evaluated and data analyzed and compiled into the clinical study report. Impact on the fiscal year ending March 2027 is currently unknown.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4889","jir_company_name":"Renascience Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4889-20261005-01.pdf","jir_short_summary":"Announced completion of enrollment for 124 patients. After up to a 3-year observation period, primary endpoints will be evaluated and data analyzed and compiled into the clinical study report. Impact on the fiscal year ending March 2027 is currently unknown.","jir_summary":"### Clinical Trial Progress and Background\nRenascience Inc. is conducting a physician-initiated Phase III randomized, placebo-controlled, double-blind clinical trial at 18 domestic sites to evaluate the combination of nivolumab and the PAI-1 inhibitor RS5614 for the treatment of unresectable malignant melanoma. This trial aims to assess the efficacy and safety of RS5614, and reached the target enrollment of 124 patients on October 5, 2026. The data will be analyzed after an observation period of up to three years and compiled into a clinical study report.\n\n### Key Points on the Drug and Market Background\nRS5614 is a small-molecule PAI-1 inhibitor that has shown oral convenience and a favorable safety profile, and may become a new treatment option for malignant melanoma. It has been designated as an orphan drug, which is expected to provide benefits such as market exclusivity post-approval and prioritized review.","jir_financial_highlights":"Timing of impact: There is currently no particular impact on the fiscal year ending March 2027","jir_category":"","jir_hashtags":"#RenascienceInc_none, #ClinicalTrialProgress","jir_key_figures":"Number of enrolled patients: 124 patients (target)\nObservation period: up to 3 years\nOrphan drug designation: Registered (2024\/8\/28)","jir_meta_title":"Renascience Inc. \u2014 Notice of Completion of Clinical Trial Enrollment\uff5cOctober 2026","jir_meta_description":"Renascience Inc. announced that enrollment reached 124 patients in the Phase III trial of nivolumab combined with RS5614. Primary endpoint evaluation and data analysis will be conducted after a 3-year observation period. Impact on the fiscal year ending March 2027 is currently unknown.","jir_og_title":"Renascience Inc. \u2014 Notice of Completion of Clinical Trial Enrollment\uff5cOctober 2026","jir_og_description":"Reported completion of enrollment for 124 patients. Evaluation and analysis will be performed after the observation period. Impact on the fiscal year ending March 2027 is currently unknown.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-127452","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n